Aethlon Medical Q3 net loss narrows to $1.8M; first patient treated in Hemopurifier cancer trial

AETHLON MEDICAL INC

2025-Q3 EPS reported -$0.61 vs consensus -$3.74 ▲ beat (+83.7%)

Cash balance $4.8M at Dec 31, 2024; operating expenses down 50% YoY to $1.8M.
First Hemopurifier treatment completed Jan 29, 2025 at Royal Adelaide Hospital with no device-related issues.
Net loss improved to $1.8M ($3.5M Q3 2023) due to cost cuts and lower separation expenses.
Protocol amendment approved at all three Australian sites to accelerate enrollment by removing run-in period.
Third clinical site (Genesis Care/Royal North Shore) to activate Feb 14, 2025; India site awaits CDSCO approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.